0.08
-2.50%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ReNerve
Its shares trade on ASX under the ticker RNV.AX. It has been listed since 26 November 2024. In the fiscal year to 30 June 2026, it reported revenue of A$510,357 and a net loss of A$5.6m. At that date it held total assets of A$4.5m and shareholders' equity of A$3.2m.
ReNerve Ltd is a AU-based company operating in Health Care Equipment & Supplies industry. ReNerve Limited is an Australia-based medical device company developing tissue-based products for peripheral nerve repair and replacement and other related soft tissue surgical procedures. The company is focused on developing products that accelerate tissue regeneration while preventing scarring and negative inflammatory responses. Its products include NervAlign Nerve Cuff, NervAlign Nerve Graft and NervAlign Bionic Nerve. NervAlign Nerve Cuff is a soft, compatible protective wrap used to protect repaired injured nerves. The product is being developed for the surgical repair of transected (cut) and damaged nerves. NervAlign nerve grafts offers surgeons the ability to repair damaged nerves (neurotmesis) without the need to harvest the sural nerve from the patient. The company is developing, NervAlign Bionic Nerve, a combination polymer technology and its nerve graft to produce a replacement nerve that contains shaped ionic polymers which would enable the stimulation of the distal end of a nerve injury.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 26 Nov 2024
- Website
- renerve.com.au ↗
Leadership
Pay as last reported
- Mr. Reginald CooperIndependent Chairman of the Board
- Dr. Julian ChickChief Executive Officer, Executive Director, since 2016
- Mr. David LiljaChief Financial Officer, Company Secretary
- Dr. David RhodesChief Scientific Officer, Executive Director, since 2016
- Dr. Michael PanaccioIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ReNerve Ltd develops tissue-based products for peripheral nerve repair in Australia.
- NervAlign Nerve Cuff protects repaired injured nerves during surgical procedures.
- NervAlign Nerve Grafts allow surgeons to repair damaged nerves without harvesting sural nerves.
Weaknesses
- The company is still developing NervAlign Bionic Nerve technology for clinical use.
- ReNerve Limited focuses only on specific soft tissue surgical procedures currently.
- Products are not yet widely available for general peripheral nerve replacement.
Opportunities
- NervAlign Bionic Nerve could enable stimulation of the distal end of nerve injuries.
- Preventing scarring offers advantages in soft tissue surgical procedures for patients.
- Accelerating tissue regeneration addresses unmet needs in peripheral nerve repair markets.
Threats
- Negative inflammatory responses remain a challenge for tissue-based product development.
- Scarring risks persist despite efforts to prevent them in surgical outcomes.
- Complex polymer technology in NervAlign Bionic Nerve faces development hurdles.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.